Trevi Therapeutics Inc (TRVI)

Nov 9, 2026

Trevi Therapeutics reported Q3 2026 financial results, highlighting the initiation of OCEAN-1 and OCEAN-2 trials for IPF-related chronic cough, with readouts expected in H2 2027 and H1 2028, respectively. The company also announced plans for a Phase 2 dose-ranging study for non-IPF ILD cough to begin in Q1 2027, with top-line data anticipated in H1 2028. With $299 million in cash, Trevi Therapeutics has funding into 2030, covering clinical trials and pre-commercial activities, and aims to be a leader in chronic cough therapies.

Nov 9, 2026

Trevi Therapeutics announced its third-quarter 2026 financial results and provided business updates, highlighting active enrollment in all three Phase 3 OCEAN trials for IPF-related chronic cough. The company also reported a positive meeting with the FDA for its non-IPF ILD-related chronic cough program, with a Phase 2 trial expected to start in Q1 2027. Trevi Therapeutics ended the quarter with $299.4 million in cash, projecting a cash runway into 2030 to fund key clinical milestones.